This study is testing a drug called YN001 in adults with coronary atherosclerosis (a condition where plaque builds up in the arteries of the heart). The goal is to see how well YN001 works and if it's safe when given intravenously (through a vein). You would be between 18 and 80 years old and already receiving treatment for heart disease risk factors. Researchers will compare YN001 at two different doses (20mg and 40mg) to a placebo (an inactive substance). The main way they'll measure success is by looking at changes in coronary NCPV (a measure of plaque) after 13 weeks. The current status of this study is unclear, but it plans to enroll 456 participants.

Study design

This is a randomized, double-blind, placebo-controlled study involving 456 participants. It compares YN001 to a placebo.

What's involved

You would receive weekly intravenous doses of YN001 or placebo for 13 weeks. The study involves a screening period, treatment period, and safety follow-up.

Compensation

Not stated in the trial record.

Follow-up

After the 13-week treatment, there will be a 30-day safety follow-up and a long-term follow-up for about 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.